[Federal Register Volume 71, Number 31 (Wednesday, February 15, 2006)]
[Notices]
[Pages 7973-7974]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-2071]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Request for Nominations for Voting Members on Public Advisory 
Committees

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting 
nominations for voting members to serve on the Allergenic Products 
Advisory Committee, Blood Products Advisory Committee, Cellular, Tissue 
and Gene Therapies Advisory Committee, Transmissible Spongiform 
Encephalopathies Advisory Committee, and the Vaccines and Related 
Biological Products Advisory Committee in the Center for Biologics 
Evaluation and Research (CBER). Nominations will be accepted for 
vacancies that will or may occur through December 31, 2006.
    FDA has a special interest in ensuring that women, minority groups, 
and individuals with disabilities are adequately represented on 
advisory committees and, therefore, encourages nominations of qualified 
candidates from these groups.

DATES: Because scheduled vacancies occur on various dates throughout 
each year, no cutoff date is established for the receipt of 
nominations. However, when possible, nominations should be received at 
least 6 months before the date of scheduled vacancies for each year, as 
indicated in this notice.

ADDRESSES: All nominations and curricula vitae should be sent to the 
contact person listed in the FOR FURTHER INFORMATION CONTACT section of 
this document.

FOR FURTHER INFORMATION CONTACT: Donald Jehn, Division of Scientific 
Advisors and Consultants, Center for Biologics Evaluation and Research 
(HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, 
MD 20852-1448, 301-827-0314, e-mail: [email protected].

SUPPLEMENTARY INFORMATION: FDA is requesting nominations of voting 
members with appropriate expertise for vacancies listed as follows:

                                Table 1.
------------------------------------------------------------------------
    Advisory Committee and
   Expertise Needed to Fill      No. of Vacancies      Approximate Date
          Vacancies                                   Members are Needed
------------------------------------------------------------------------
Allergenic Products Advisory   1                     As soon as possible
 Committee--allergy,           1                     August 31, 2006
 immunology, pediatrics,
 internal medicine,
 biochemistry, statistics,
 and related scientific
 fields
------------------------------------------------------------------------
Blood Products Advisory        2                     As soon as possible
 Committee--clinical and       1                     September 30, 2006
 administrative medicine,
 hematology, immunology,
 blood banking, surgery,
 internal medicine,
 biochemistry, engineering,
 statistics, biological and
 physical sciences,
 biotechnology, computer
 technology, epidemiology,
 consumer advocacy, sociology/
 ethics, and other related
 professions
------------------------------------------------------------------------

[[Page 7974]]

 
Cellular, Tissue, and Gene     2                     March 31, 2006
 Therapies Advisory
 Committee--cellular
 therapies, tissue
 transplantation, gene
 transfer therapies and
 xenotransplantation
 including biostatistics,
 bioethics, hematology/
 oncology, human tissues and
 transplantation,
 reproductive medicine,
 general medicine and various
 medical specialties
 including surgery and
 oncology, immunology,
 virology, molecular biology,
 cell biology, developmental
 biology, tumor biology,
 biochemistry, rDNA
 technology, nuclear
 medicine, gene therapy,
 infectious diseases, and
 cellular kinetics
------------------------------------------------------------------------
Transmissible Spongiform       3                     As soon as possible
 Encephalopathies Advisory
 Committee--clinical and
 administrative medicine,
 hematology, virology,
 neurovirology, neurology,
 infectious diseases,
 immunology, transfusion
 medicine, surgery, internal
 medicine, biochemistry,
 biostatistics, epidemiology,
 biological and physical
 sciences, consumer advocacy,
 sociology/ethics, and other
 related professions
------------------------------------------------------------------------
Vaccines and Related           4                     As soon as possible
 Biological Products Advisory
 Committee--immunology,
 molecular biology, rDNA,
 virology, bacteriology,
 epidemiology, biostatistics,
 allergy, preventive
 medicine, infectious
 diseases, pediatrics,
 microbiology, biochemistry,
 and other related scientific
 fields
------------------------------------------------------------------------

I. Functions

A. Allergenic Products Advisory Committee

    The committee reviews and evaluates available data concerning the 
safety, effectiveness, and adequacy of labeling of marketed and 
investigational allergenic biological products or materials that are 
administered to humans for the diagnosis, prevention, or treatment of 
allergies and allergic diseases.

B. Blood Products Advisory Committee

    The committee reviews and evaluates available data concerning the 
safety, effectiveness, and appropriate use of blood and products 
derived from blood and serum or biotechnology which are intended for 
use in the diagnosis, prevention, or treatment of human diseases.

C. Cellular, Tissue and Gene Therapies Advisory Committee

    The committee reviews and evaluates available data relating to the 
safety, effectiveness, and appropriate use of human cells, human 
tissues, gene transfer therapies and xenotransplantation products which 
are intended for transplantation, implantation, infusion, and transfer 
in the prevention and treatment of a broad spectrum of human diseases 
and in reconstruction, repair, or replacement of tissues for various 
conditions.

D. Transmissible Spongiform Encephalopathies Advisory Committee

    The committee reviews and evaluates available scientific data 
concerning the safety of products which may be at risk for transmission 
of spongiform encephalopathies having an impact on the public health.

E. Vaccines and Related Biological Products Advisory Committee

    The committee reviews and evaluates data concerning the safety, 
effectiveness, and appropriate use of vaccines and related biological 
products which are intended for use in the prevention, treatment, or 
diagnosis of human diseases.

II. Qualifications

    Persons nominated for membership on the committees shall have 
adequately diversified experience appropriate to the work of the 
committee in such fields as clinical and administrative medicine, 
engineering, biological and physical sciences, statistics, and other 
related professions. The nature of specialized training and experience 
necessary to qualify the nominee as an expert suitable for appointment 
may include experience in medical practice, teaching, and/or research 
relevant to the field of activity of the committee. The particular need 
for vacancies on each committee for the calendar year 2006 is shown in 
Table 1 of this document. The term of office is up to 4 years, 
depending on the appointment date.

III. Nomination Procedures

    Any interested person may nominate one or more qualified persons 
for membership on one or more of the advisory committees. Self-
nominations are also accepted. Nominations shall include the name of 
the committee, a complete curriculum vitae of each nominee, current 
business address and telephone number, and shall state that the nominee 
is aware of the nomination, is willing to serve as a member (name of 
committee(s) must be specified), and appears to have no conflict of 
interest that would preclude membership. FDA will ask the potential 
candidates to provide detailed information concerning such matters as 
financial holdings, employment, and research grants and/or contracts to 
permit evaluation of possible sources of conflict of interest.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

    Dated: February 7, 2006.
Jason Brodsky,
Acting Associate Commissioner for External Relations.
[FR Doc. E6-2071 Filed 2-14-06; 8:45 am]
BILLING CODE 4160-01-S